Castrate Resistant Prostrate Cancer Pipeline Insights, Treatment Drugs, Clinical Trials, And Companies 2024

DelveInsight's,
“Castrate Resistant Prostrate Cancer Pipeline Insight, 2024,”
report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Castrate Resistant Prostrate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Castrate Resistant Prostrate Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Castrate Resistant Prostrate Cancer Pipeline Outlook

Key Takeaways from the Castrate Resistant Prostrate Cancer Pipeline Report

• In September 2024:- Bayer - A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC).
• DelveInsight's Castrate Resistant Prostrate Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Castrate Resistant Prostrate Cancer treatment.
• The leading Castrate Resistant Prostrate Cancer Companies such as Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma , and others.
• Promising Castrate Resistant Prostrate Cancer Therapies such as Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab , and others.

Stay ahead with the most recent pipeline outlook for Castrate Resistant Prostrate Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Castrate Resistant Prostrate Cancer Treatment Drugs

Castrate Resistant Prostrate Cancer Emerging Drugs

• Niraparib: Janseen

Niraparib is highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. Niraparib is currently investigated by Janssen Research & Development.

• Nivolumab: Bristol-Myers Squibb

Nivolumab by Bristol-Myers Squibb is a human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1, with immune checkpoint inhibitory and antineoplastic activities. BMS is working on assessing the clinical activity seen with Nivolumab in combination with docetaxel in male patients with metastatic castration-resistant prostate cancer.

Explore groundbreaking therapies and clinical trials in the Castrate Resistant Prostrate Cancer Pipeline. Access DelveInsight's detailed report now! @ New Castrate Resistant Prostrate Cancer Drugs

Castrate Resistant Prostrate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.
• Molecule Type

Castrate Resistant Prostrate Cancer Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Unveil the future of Castrate Resistant Prostrate Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Castrate Resistant Prostrate Cancer Market Drivers and Barriers

Scope of the Castrate Resistant Prostrate Cancer Pipeline Report

• Coverage- Global
• Castrate Resistant Prostrate Cancer Companies- Janseen, Bristol-Myers Squibb, AB Science, Newsoara Biopharma, ESSA Pharma, and others.
• Castrate Resistant Prostrate Cancer Therapies- Etrumadenant, Zimberelimab, Quemliclustat, PF-06821497, Pembrolizumab, and others.
• Castrate Resistant Prostrate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Castrate Resistant Prostrate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Castrate Resistant Prostrate Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Castrate Resistant Prostrate Cancer Companies, Key Products and Unmet Needs

Table of Content